These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2796859)

  • 1. Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphoblastic leukemia.
    Ishii E; Yamada S; Higuchi S; Honjo T; Igarashi H; Kanemitsu S; Kai T; Ueda K
    Med Pediatr Oncol; 1989; 17(5):429-32. PubMed ID: 2796859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral mucositis.
    Albertioni F; Rask C; Schroeder H; Peterson C
    Anticancer Drugs; 1997 Feb; 8(2):119-24. PubMed ID: 9073308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
    Rask C; Albertioni F; Schrøder H; Peterson C
    Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
    Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
    Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate-induced oral mucositis and salivary methotrexate concentrations.
    Oliff A; Bleyer WA; Poplack DG
    Cancer Chemother Pharmacol; 1979; 2(3):225-6. PubMed ID: 313282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A decrease in vitamin D levels is associated with methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
    Oosterom N; Dirks NF; Heil SG; de Jonge R; Tissing WJE; Pieters R; van den Heuvel-Eibrink MM; Heijboer AC; Pluijm SMF
    Support Care Cancer; 2019 Jan; 27(1):183-190. PubMed ID: 29922939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global methylation in relation to methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
    Oosterom N; Griffioen PH; den Hoed MAH; Pieters R; de Jonge R; Tissing WJE; van den Heuvel-Eibrink MM; Heil SG
    PLoS One; 2018; 13(7):e0199574. PubMed ID: 29985926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.
    Sari NM; Rakhmilla LE; Bashari MH; Zazuli Z; Suryawan N; Susanah S; Reniarti L; Raspati H; Supriyadi E; Kaspers GJL; Idjradinata P
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2025-2031. PubMed ID: 34319023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
    Oosterom N; Berrevoets M; den Hoed MAH; Zolk O; Hoerning S; Pluijm SMF; Pieters R; de Jonge R; Tissing WJE; van den Heuvel-Eibrink MM; Heil SG
    Pharmacogenet Genomics; 2018 Oct; 28(10):223-229. PubMed ID: 30222710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia--a logistic regression analysis.
    Rask C; Albertioni F; Bentzen SM; Schroeder H; Peterson C
    Acta Oncol; 1998; 37(3):277-84. PubMed ID: 9677100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
    Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
    J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral mucositis and saliva IgA, IgG and IgM concentration during anti-tumor treatment in children suffering from acute lymphoblastic leukemia.
    Pels EJ
    Adv Clin Exp Med; 2017 Dec; 26(9):1351-1358. PubMed ID: 29442455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
    Lange BJ; Blatt J; Sather HN; Meadows AT
    Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer.
    Cheng KK
    Eur J Cancer Care (Engl); 2008 May; 17(3):306-11. PubMed ID: 18419635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
    Relling MV; Fairclough D; Ayers D; Crom WR; Rodman JH; Pui CH; Evans WE
    J Clin Oncol; 1994 Aug; 12(8):1667-72. PubMed ID: 8040679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study on the pharmacokinetics of 7-hydroxy-methotrexate after administration of methotrexate in the dose range of 0.5-33.6 g/m2 to children with acute lymphoblastic leukemia.
    Borsi JD; Sagen E; Romslo I; Moe PJ
    Med Pediatr Oncol; 1990; 18(3):217-24. PubMed ID: 2329967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia.
    Driehuis E; Oosterom N; Heil SG; Muller IB; Lin M; Kolders S; Jansen G; de Jonge R; Pieters R; Clevers H; van den Heuvel-Eibrink MM
    PLoS One; 2020; 15(5):e0231588. PubMed ID: 32421698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
    Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
    Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.